Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
57 hedge funds and large institutions have $12.6M invested in Checkpoint Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 9 closing their positions.
23% more capital invested
Capital invested by funds: $10.3M → $12.6M (+$2.34M)
0.14% more ownership
Funds ownership: 1.19% → 1.33% (+0.14%)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
8% less funds holding
Funds holding: 62 → 57 (-5)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
57% less call options, than puts
Call options by funds: $411K | Put options by funds: $957K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JSMC
Jess S. Morgan & Co
Los Angeles,
California
|
+$902K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$341K |
| 3 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$105K |
| 4 |
AI
Atom Investors
Austin,
Texas
|
+$81.9K |
| 5 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$64.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$473K |
| 2 |
Millennium Management
New York
|
-$343K |
| 3 |
Two Sigma Investments
New York
|
-$88.5K |
| 4 |
Two Sigma Advisers
New York
|
-$84.5K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$60.3K |
CKPT Hedge Fund Activity: Q3 2022 in Review
57 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q3 2022, worth a combined $12.6M — up 23% from $10.3M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CKPT and 5 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 12 added.
The largest buyer was Jess S. Morgan & Co, adding an estimated $902K. The largest seller was Renaissance Technologies, cutting an estimated $473K.
- 57 institutional investors held Checkpoint Therapeutics (CKPT) as of Q3 2022, down from 62 in Q2 2022.
- Funds reported $12.6M of Checkpoint Therapeutics stock for Q3 2022, up 23% quarter-over-quarter.
- 5 funds opened new Checkpoint Therapeutics positions in Q3 2022 and 9 closed out, a net change of -4 holders.
- The largest Checkpoint Therapeutics buyer in Q3 2022 was Jess S. Morgan & Co, an estimated $902K added.
- The largest Checkpoint Therapeutics seller in Q3 2022 was Renaissance Technologies, an estimated $473K sold.
Based on aggregated 13F filings for Q3 2022.